EGFR and non-small cell lung carcinoma: At the same time, this analysis also showed that the incidence of grade 2 and above RP in NSCLC patients who used first-generation EGFR-TKIs and chest radiotherapy was as high as 44.78%, and 8.96% of these patients had grade 3 RP.